Resolution of a Contraceptive-Steroid-Induced Hepatic Adenoma with Subsequent Evolution into Hepatocellular Carcinoma

1986 ◽  
Vol 105 (4) ◽  
pp. 547 ◽  
Author(s):  
STUART C. GORDON
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Adenoma ◽  
Subsequent Evolution ◽  
Contraceptive Steroid

scholarly journals A rare case of hepatocellular carcinoma arising from gadoxetate-retaining hepatic adenoma

2020 ◽  
Vol 15 (2) ◽  
pp. 141-143 ◽  
Author(s):  
Mario A. Cedillo ◽  
Joshua Wong ◽  
Joseph W. Song ◽  
Joseph Liao
Keyword(s):  
Hepatocellular Carcinoma ◽  
Rare Case ◽  
Hepatic Adenoma

scholarly journals Hepatocellular carcinoma arising from hepatic adenoma in a young woman

2020 ◽  
Vol 8 (9) ◽  
pp. 1659-1662
Author(s):  
Haythem Yacoub ◽  
Hela Kchir ◽  
Dhouha Cherif ◽  
Hajer Hassine ◽  
Slim Haouet ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Young Woman ◽  
Hepatic Adenoma

Hepatic Adenoma Arising in a Patient With Alagille Syndrome: A Case Report

2018 ◽  
Vol 21 (6) ◽  
pp. 585-589 ◽  
Author(s):  
M Cristina Pacheco ◽  
Eric J Monroe ◽  
Simon P Horslen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Vertebral Body ◽  
Bile Ducts ◽  
Alagille Syndrome ◽  
Hepatic Adenoma ◽  
Clinical Imaging ◽  
Cardiac Abnormalities ◽  
Regenerative Nodules

Alagille syndrome is associated with decreased bile ducts, cardiac abnormalities, vertebral body fusion defects, and a typical facies. While regenerative nodules and hepatocellular carcinoma have been described in these patients, hepatic adenoma has not. Herein, we present a patient with Alagille syndrome caused by a mutation in NOTCH2 with a hepatic adenoma. The clinical, imaging, and histologic features are discussed.

Hepatic adenoma masquerading as a hepatocellular carcinoma in a patient with a Fontan procedure on the oral contraceptive pill

2021 ◽  
Vol 51 (4) ◽  
pp. 613-615
Author(s):  
Jessica V. Yao ◽  
Siddharth Sood ◽  
Julie Lokan ◽  
Anand Murugasu ◽  
Leeanne Grigg ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Oral Contraceptive ◽  
Fontan Procedure ◽  
Oral Contraceptive Pill ◽  
Hepatic Adenoma ◽  
Contraceptive Pill

Best Practices in Diagnostic Immunohistochemistry: Hepatocellular Carcinoma Versus Metastatic Neoplasms

2007 ◽  
Vol 131 (11) ◽  
pp. 1648-1654 ◽  
Author(s):  
Sanjay Kakar ◽  
Allen M. Gown ◽  
Zachary D. Goodman ◽  
Linda D. Ferrell
Keyword(s):  
Hepatocellular Carcinoma ◽  
Best Practices ◽  
English Literature ◽  
Research Articles ◽  
Hepatic Adenoma ◽  
Fine Needle ◽  
Immunohistochemical Markers ◽  
Poorly Differentiated ◽  
Low Sensitivity ◽  
Selection Of

Abstract Context.—Immunohistochemistry plays a crucial role in the diagnosis of hepatocellular carcinoma and in its distinction from other primary and metastatic neoplasms. Because limited tissue is available with fine-needle and core biopsies, appropriate selection of antibodies is imperative. Objective.—To review the antibodies used for the diagnosis of hepatocellular carcinoma and to outline an immunohistochemical approach in commonly encountered clinical situations. Data Sources.—Our experience and review of research articles published in the English literature between 1987 and 2006. Conclusions.—Hep Par 1 and polyclonal carcinoembryonic antigen are the most reliable markers for hepatocellular differentiation, but they have low sensitivity for poorly differentiated cases. Immunohistochemistry for glypican-3 shows promise for the diagnosis of poorly differentiated hepatocellular carcinoma and for its distinction from benign processes such as hepatic adenoma. Further studies with a large number of cases are required before it can be widely used. The combination of Hep Par 1 and MOC-31 will allow for the diagnosis of hepatocellular carcinoma in most cases and will guide the selection of immunohistochemical markers for further workup.

Sign in / Sign up

Export Citation Format

Share Document